# OS Therapies Closes $7.2 Million Warrant Exercise Offer With Nine Investors

> OS Therapies closed a warrant exercise inducement offer with nine accredited investors, raising $7.2 million in gross proceeds for Herlystic regulatory filings.

- Published: 2026-10-19T13:02:06+00:00
- Section: Funding
- Author: News Desk
- URL: https://newsforagent.com/news/2026-10-19/os-therapies-warrant-exercise-offer-closing
- Source: [Aktien](https://www.wallstreet-online.de/nachricht/21546677-os-therapies-announces-initial-closing-of-warrant-exercise-inducement-and-exchange-offer-for-initial-gross-proceeds-of-approximately-7-2-million)

## Key takeaways

- OS Therapies raised $7.2 million in gross proceeds from seven holders exercising or pre-funding warrants at a reduced price of $1.30 per share.
- The company issued new warrants to purchase up to 5,517,253 shares at $1.40 per share and the offer expires on October 30, 2026.
- OS Therapies has accrued $7 million in refundable U.K. research and development tax credits, with the filing expected in the fourth quarter of 2026.

[OS Therapies](https://akta.pro/company-profiles/00004yb/os-therapies) Inc. closed the initial phase of a warrant exercise inducement and exchange offer with nine accredited investors, raising approximately $7.2 million in gross proceeds, according to [Aktien](https://www.wallstreet-online.de/nachricht/21546677-os-therapies-announces-initial-closing-of-warrant-exercise-inducement-and-exchange-offer-for-initial-gross-proceeds-of-approximately-7-2-million). The company said seven holders exercised or pre-funded warrants to purchase 5,517,253 shares at a reduced exercise price of $1.30 per share.

## OS Therapies Warrant Exercise and New Warrants

The offer was made to nine accredited investors who beneficially owned common stock purchase warrants. At the initial closing, seven holders exercised or pre-funded their existing warrants, resulting in the $7.2 million in gross proceeds before deducting solicitation agent fees and other offering expenses. A significant majority of the exercised warrants carried an exercise price of $1.40 per share.

In consideration for the exercise or pre-funding, OS Therapies issued new common stock purchase warrants to purchase up to an aggregate of 5,517,253 shares at an exercise price of $1.40 per share. The offer is scheduled to expire at 11:59 p.m. Eastern time on October 30, 2026, unless extended or earlier terminated, and was made only to the holders. A description of the material terms is included in the company's Current Report on Form 8-K filed with the Securities and Exchange Commission.

## OS Therapies Funding History and Tax Credits

According to [akta.pro company records](https://akta.pro/company-data), OS Therapies has completed 11 funding rounds on record, with a total funding of $56.3 million as of its last round on August 10, 2026. The company's recent capital raises include a $7.53 million warrant inducement in January 2026, a $5.7 million financing in the first quarter of 2026, a $5.25 million registered direct offering in April 2026, and a $4.2 million warrant exercise inducement in mid-2025.

| Date | Round Type | Amount |
| --- | --- | --- |
| 2026-08 | Post IPO debt | $5.4 million |
| 2026-08 | Post IPO equity | $2.2 million |
| 2026-07 | Post IPO debt | $10 million |
| 2026-06 | Post IPO debt | $1.6 million |

The company has also accrued $7 million in refundable research and development tax credits through its U.K. subsidiary. The tax credit filing with His Majesty's Revenue and Customs is expected to be submitted during the fourth quarter of 2026, with receipt of the credit expected in early 2027.

## Earlier OS Therapies Regulatory and Financing Steps

OS Therapies announced full alignment with the UK MHRA and EU EMA on its Conditional Marketing Authorisation Application for OST-HER2 in osteosarcoma in September 2026, according to Stock Titan. The World Health Organization approved the brand name Herlystic for the gene-edited cancer immunotherapy in September 2026, and the company planned to initiate regulatory submissions in the U.K.

In August 2026, OS Therapies secured up to $10 million in debt financing backed by expected U.K. VAT refunds and R&D tax credits, according to Pulse 2.0. The company reported a net operating loss of $8.576 million for the second quarter of 2026.

## OS Therapies Regulatory Submission Timeline

OS Therapies expects to complete early market access regulatory approval submissions for Herlystic in the U.S., U.K., Europe and Australia in the fourth quarter of 2026. The company said proceeds from the initial closing, together with accrued refundable U.K. R&D tax credits, are expected to provide operating runway through major upcoming milestones.

## Companies in this story

- [OS Therapies company profile](https://akta.pro/company-profiles/00004yb/os-therapies) · website: https://www.ostherapies.com

---
News for Agent · https://newsforagent.com/llms.txt